Headlines about Fresenius Medical Care Corporation (NYSE:FMS) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fresenius Medical Care Corporation earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 30 out of 100, meaning that recent media coverage is unlikely to have an impact on the company’s share price in the near term.

A number of analysts recently commented on the stock. UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Royal Bank Of Canada restated a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research report on Tuesday, July 11th. Nord/LB restated a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Finally, DZ Bank AG restated a “neutral” rating on shares of Fresenius Medical Care Corporation in a research report on Monday, May 29th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. Fresenius Medical Care Corporation has a consensus rating of “Buy” and an average target price of $48.67.

Fresenius Medical Care Corporation (NYSE FMS) opened at 49.30 on Friday. The firm has a market cap of $30.20 billion, a price-to-earnings ratio of 21.04 and a beta of 0.48. The stock has a 50 day moving average of $47.75 and a 200-day moving average of $43.48. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings data on Wednesday, May 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.09. Fresenius Medical Care Corporation had a return on equity of 11.79% and a net margin of 7.24%. The business had revenue of $4.55 billion during the quarter, compared to analyst estimates of $4.69 billion. During the same period in the previous year, the firm earned $0.75 EPS. On average, analysts expect that Fresenius Medical Care Corporation will post $2.28 EPS for the current year.

WARNING: “Somewhat Favorable Press Coverage Unlikely to Affect Fresenius Medical Care Corporation (FMS) Share Price” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/07/16/fresenius-medical-care-corporation-fms-earns-daily-coverage-optimism-score-of-0-18-updated-updated-updated.html.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Insider Buying and Selling by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.